Weixinkang’s subsidiary potassium magnesium aspartate injection passed the consistency evaluation
April 24, 2025
Source: drugdu
57
April 22, Weixinkang(603676) issued an announcement that recently, the company's wholly-owned subsidiary Baiyi Pharmaceutical received the "Notice of Approval of Drug Supplementary Application" for potassium magnesium aspartate injection approved and issued by the National Medical Products Administration. The drug successfully passed the generic drug quality and efficacy consistency evaluation.
Potassium magnesium aspartate injection is an electrolyte supplement used for the auxiliary treatment of hypokalemia, arrhythmias (mainly ventricular arrhythmias) caused by digitalis poisoning, and sequelae of myocarditis, congestive heart failure, and myocardial infarction.
As of the end of March 2025, the company's cumulative investment in research and development of this drug was RMB 2.0615 million (unaudited).
In the first three quarters of 2024, Weixinkang achieved revenue of 994 million yuan and net profit attributable to shareholders of the parent company of 243 million yuan.
https://finance.eastmoney.com/a/202504223384343433.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Fudan University establishes the “Baili Tianheng Distinguished Professor” program May 14, 2025
- If you don’t lower, don’t sell! Trump enforces minimum drug prices in developed countries, but litigation war may ‘repeat’ May 14, 2025
- Barriers and Pathways to Healthtech Adoption in Clinical Practice May 14, 2025
- US Health Officials Advise Older Travelers Not to Get a Chikungunya Vaccine May 14, 2025
- Laimi Pharmaceuticals receives approval for supplemental application for naloxone hydrochloride injection May 14, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
